Comparing two assays for clinical genomic profiling: The devil is in the data

OncoTargets and Therapy

Volumn 8, Issue , 2015, Pages 2237-2242

  Squillace, Rachel M ^a   Frampton, Garrett M ^a   Stephens, Phil J ^a   Ross, Jeffrey S ^a   Miller, Vincent A ^a  

^a FOUNDATION MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; K RAS PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLATELET DERIVED GROWTH FACTOR A; RNA;

ADVANCED CANCER; ASSAY; CANCER GENOME PROFILING ASSAY; COLON ADENOCARCINOMA; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; GENOMICS; HUMAN; IMMUNOHISTOCHEMISTRY; LETTER; LUNG ADENOCARCINOMA; MEDICAL DECISION MAKING; NEXT GENERATION SEQUENCING; PATIENT CARE;

EID: 84940069130     PISSN: None     EISSN: 11786930     Source Type: Journal    
DOI: 10.2147/OTT.S88908     Document Type: Letter

References (10)

1. Weiss GJ, Hoff BR, Whitehead RP, et al. Evaluation and comparison of two commercially available targeted next-generation sequencing platforms to assist oncology decision making. Onco Targets Ther. 2015;8:959–967.
2. Frampton GM, Fichtenholtz A, Otto GA, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol. 2013;31(11):1023–1031.
3. Marsh DJ, Trahair TN, Martin JL, et al. Rapamycin treatment for a child with germline PTEN mutation. Nat Clin Pract Oncol. 2008;5(6):357–361.
4. Cheng H, Piperdi B, Zou Y, et al. 335 RICTOR amplification as a novel molecular target for the treatment of lung cancer. Eur J Cancer. 2014;50 Suppl 6:108–109.
5. Borad MJ, Champion MD, Egan JB, et al. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PLoS Genet. 2014;10(2):e1004135.
6. Villaruz LC, Socinski MA. Temsirolimus therapy in a patient with lung adenocarcinoma harboring an FBXW7 mutation. Lung Cancer. 2014;83(2):300–301.
7. Jänne PA, Shaw AT, Pereira JR, et al. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol. 2013;14(1):38–47.
8. Goswami PC, Roti Roti JL, Hunt CR. The cell cycle-coupled expression of topoisomerase IIα during S phase is regulated by mRNA stability and is disrupted by heat shock or ionizing radiation. Mol Cell Biol. 1996;16(4):1500–1508.
9. Mueller RE, Parkes RK, Andrulis I, O’Malley FP. Amplification of the TOP2A gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samples. Genes Chromosomes Cancer. 2004;39(4):288–297.
10. Desmedt C, Di Leo A, de Azambuja E, et al. Multifactorial approach to predicting resistance to anthracyclines. J Clin Oncol. 2011;29(12):1578–1586.